SPA-S-753/spk-843 :::

new antifungal agent

The new antifungal SPA-S-753/SPK-843 has reached the clinical stage

" A single, ascending dose, safety, tolerability and pharmacokinetic phase I study in healthy volunteers with the new antifungal agent SPK-843 has been completed without showing any serious local or systemic adverse reaction. The study has been GCP-conform and carried out with double blind treatment.
SPK-843 has main indication in the treatment of severe deep-seated infections by Candida, Aspergillus, Cryptococcus and other sensitive microorganisms by means of slow intravenous infusion.
In experimental tests in vitro and in vivo, it proved to be the most potent and effective of all antifungals known, particularly in the immunocompromised host, and is also better tolerated than amphotericin B-like compounds.
The new Dutch Company APARTS BV based in Rotterdam has acquired worldwide rights for its development.
Licence for Japan has been assigned, while contacts are still pending with US and European Companies. "

Copyright 2003 - Aparts B.V. The Netherlands - apartsbv@apartsbv.com